DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 17:59:46 31/05/2024 BST | ||
| 274.4 EUR | -0.02% |
|
| Current month | -0.74% | ||
| 1 month | -0.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 274.4 | -0.02% |
| 30/05/24 | 274.5 | -0.21% |
| 29/05/24 | 275.1 | +0.58% |
| 28/05/24 | 273.5 | -0.18% |
| 27/05/24 | 274 | -0.08% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 05:59 pm
More quotesStatic data
| Product type | Certificati Discount |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8N |
| ISIN | DE000ME7D8N7 |
| Date issued | 23/01/2024 |
| Maturity | 20/09/2024 (112 Days) |
| Parity | 1 : 1 |
| Emission price | 268.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 276.4 € |
|---|---|
| Lowest since issue | 263 € |
| Spread | 0.32 € |
| Spread % | 0.12% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
